MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13023-022-02547-8

Медицинская библиотека · Orphanet journal of rare diseases · 2022

Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study.

Pechmann Astrid, Behrens Max, Dörnbrack Katharina, Tassoni Adrian, Wenzel Franziska, Stein Sabine, Vogt Sibylle, Zöller Daniela, Bernert Günther, Hagenacker Tim, Schara-Schmidt Ulrike, Walter Maggie C, Bertsche Astrid, Vill Katharina, Baumann Matthias, Baumgartner Manuela, Cordts Isabell, Eisenkölbl Astrid, Flotats-Bastardas Marina, Friese Johannes, Günther René, Hahn Andreas, Horber Veronka, Husain Ralf A, Illsinger Sabine, Jahnel Jörg, Johannsen Jessika, Köhler Cornelia, Kölbel Heike, Müller Monika, von Moers Arpad, Schwerin-Nagel Annette, Reihle Christof, Schlachter Kurt, Schreiber Gudrun, Schwartz Oliver, Smitka Martin, Steiner Elisabeth, Trollmann Regina, Weiler Markus, Weiß Claudia, Wiegand Gert, Wilichowski Ekkehard, Ziegler Andreas, Lochmüller Hanns, Kirschner Janbernd, SMArtCARE study group

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

The development and approval of disease modifying treatments have dramatically changed disease progression in patients with spinal muscular atrophy (SMA). Nusinersen was approved in Europe in 2017 for the treatment of SMA patients irrespective of age and disease severity. Most data on therapeutic efficacy are available for the infantile-onset SMA. For patients with SMA type 2 and type 3, there is still a lack of sufficient evidence and long-term experience for nusinersen treatment. Here, we report data from the SMArtCARE registry of non-ambulant children with SMA type 2 and typen 3 under nusinersen treatment with a follow-up period of up to 38 months.

METHODS

SMArtCARE is a disease-specific registry with data on patients with SMA irrespective of age, treatment regime or disease severity. Data are collected during routine patient visits as real-world outcome data. This analysis included all non-ambulant patients with SMA type 2 or 3 below 18 years of age before initiation of treatment. Primary outcomes were changes in motor function evaluated with the Hammersmith Functional Motor Scale Expanded (HFMSE) and the Revised Upper Limb Module (RULM).

RESULTS

Data from 256 non-ambulant, pediatric patients with SMA were included in the data analysis. Improvements in motor function were more prominent in upper limb: 32.4% of patients experienced clinically meaningful improvements in RULM and 24.6% in HFMSE. 8.6% of patients gained a new motor milestone, whereas no motor milestones were lost. Only 4.3% of patients showed a clinically meaningful worsening in HFMSE and 1.2% in RULM score.

CONCLUSION

Our results demonstrate clinically meaningful improvements or stabilization of disease progression in non-ambulant, pediatric patients with SMA under nusinersen treatment. Changes were most evident in upper limb function and were observed continuously over the follow-up period. Our data confirm clinical trial data, while providing longer follow-up, an increased number of treated patients, and a wider range of age and disease severity.

Для цитирования: Pechmann Astrid, Behrens Max, Dörnbrack Katharina, Tassoni Adrian, Wenzel Franziska, Stein Sabine, Vogt Sibylle, Zöller Daniela, Bernert Günther, Hagenacker Tim, Schara-Schmidt Ulrike, Walter Maggie C, Bertsche Astrid, Vill Katharina, Baumann Matthias, Baumgartner Manuela, Cordts Isabell, Eisenkölbl Astrid, Flotats-Bastardas Marina, Friese Johannes, Günther René, Hahn Andreas, Horber Veronka, Husain Ralf A, Illsinger Sabine, Jahnel Jörg, Johannsen Jessika, Köhler Cornelia, Kölbel Heike, Müller Monika, von Moers Arpad, Schwerin-Nagel Annette, Reihle Christof, Schlachter Kurt, Schreiber Gudrun, Schwartz Oliver, Smitka Martin, Steiner Elisabeth, Trollmann Regina, Weiler Markus, Weiß Claudia, Wiegand Gert, Wilichowski Ekkehard, Ziegler Andreas, Lochmüller Hanns, Kirschner Janbernd, SMArtCARE study group. Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study.. Orphanet journal of rare diseases. 2022. DOI: 10.1186/s13023-022-02547-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.